Methylation, Liver Health, and Performance

Evidence Review

Homocysteine Lowering Trial (Olthof et al., 2003)

This was a double-blind, placebo-controlled trial in 48 healthy adults who received 1.5, 3, or 6 grams of betaine daily for six weeks [1]. Fasting plasma homocysteine was reduced dose-dependently: by 12% at 1.5 g/day, 15% at 3 g/day, and 20% at 6 g/day compared to placebo. Even more striking, betaine at all doses reduced the post-methionine-load spike in homocysteine by 40–50%, while folic acid had no effect on this postprandial homocysteine rise. This is clinically significant because postprandial homocysteine may be a more sensitive cardiovascular risk marker than fasting levels alone. The study established that betaine's homocysteine-lowering effect is distinct from and complementary to folate and B12, operating through an entirely separate enzyme (BHMT) rather than the folate-dependent remethylation pathway.

Lipid Effects Analysis (Olthof et al., 2005)

This pooled analysis of four randomized placebo-controlled studies (total n = 180) examined the effects of betaine, folic acid, and phosphatidylcholine on both homocysteine and blood lipids [2]. While betaine significantly lowered homocysteine, it simultaneously increased LDL cholesterol (mean increase: 0.31 mmol/L, 95% CI: 0.23–0.39) and triglycerides (mean increase: 0.32 mmol/L, 95% CI: 0.07–0.57) compared to placebo. This finding substantially complicates betaine's cardiovascular risk profile: the homocysteine-lowering benefit may be partially or fully offset by the lipid-raising effect. The authors concluded that betaine supplementation for cardiovascular protection cannot be recommended on current evidence, though they noted that dietary betaine from whole foods does not appear to raise lipids — possibly because food sources come packaged with fiber and other compounds that modulate lipid absorption.

NAFLD Randomized Trial (Abdelmalek et al., 2009)

This 12-month randomized placebo-controlled trial enrolled 55 patients with biopsy-proven nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease [3]. Patients received 20 g of oral betaine daily (a very high dose) or placebo, with 34 completing follow-up liver biopsies. Betaine significantly improved the degree of hepatic steatosis (fat accumulation) compared to placebo, and steatosis worsened in more placebo patients than betaine patients. However, betaine did not significantly improve liver enzyme levels, inflammation scores, or fibrosis — the more advanced markers of disease severity. The authors noted that 20 g/day may be too high a dose for optimal SAMe generation, as it can paradoxically deplete SAMe when excessive. Despite the mixed results, this remains the most rigorous human trial of betaine for liver disease, and the steatosis finding is considered a meaningful positive signal.

Hepatoprotection Mechanism (Kathirvel et al., 2010)

This animal study examined the mechanism by which betaine protects against fatty liver and associated insulin resistance [4]. Mice fed a high-fat diet developed NAFLD and hepatic insulin resistance; betaine supplementation significantly reduced fasting glucose, plasma insulin, triglycerides, and hepatic fat accumulation compared to controls. Critically, betaine treatment restored the liver's ability to respond to insulin at the molecular signaling level (measured by phosphorylation of insulin receptor substrate proteins), suggesting betaine acts on insulin signaling pathways in the liver independently of its methyl-donating role. The study proposed that betaine's hepatoprotection involves both methylation support (maintaining SAMe levels) and direct modulation of lipid metabolism genes — a dual mechanism that may explain why whole-food betaine sources appear more protective than isolated supplements.

Muscle Performance Systematic Review (Ismaeel, 2017)

This systematic review evaluated seven randomized controlled trials of "excellent quality" examining betaine supplementation's effect on muscle strength and power in athletic populations [5]. Doses ranged from 1.25 g to 2.5 g per day, with intervention lengths of two to six weeks. Of the seven trials, only two (29%) reported significant improvements in strength or power outcomes; the remaining five found no significant effect. The heterogeneity across trials was explained partly by differences in training status, type of exercise tested (strength vs. power vs. endurance), and measurement methods. The author concluded there is insufficient evidence to support betaine as a reliable ergogenic for strength and power, though noted that work capacity and endurance-type outcomes showed more promising signals in the included studies. The review highlighted that athletes with high protein intakes may represent a subgroup where betaine's methyl-donating role is more relevant.

Cardiovascular Markers Meta-Analysis (Ashtary-Larky et al., 2021)

This meta-analysis of 24 randomized controlled trials examined betaine supplementation's effects on a comprehensive panel of cardiovascular markers [6]. Betaine significantly reduced total homocysteine (mean difference: −3.09 μmol/L), total cholesterol (increased — a notable negative finding), and LDL cholesterol (increased). Triglycerides, HDL, fasting blood glucose, CRP, and liver enzymes were not significantly affected overall. The analysis confirmed the dose-dependent homocysteine-lowering effect and also confirmed the lipid-raising concern seen in earlier studies. Subgroup analyses suggested that lower doses (under 4 g/day) produced smaller LDL increases, while higher doses showed greater lipid perturbation. The authors concluded that betaine may benefit cardiovascular health through homocysteine reduction but that this benefit may be counteracted by its pro-lipid effects, particularly at higher doses. They recommended that future trials incorporate full lipid panels alongside homocysteine measures.